Your Partner in Health Solutions to Support COVID-19 Response Efforts

Masimo supports surge capacity efforts with a range of noninvasive monitoring and ancillary single-use solutions that can help care teams prepare for and manage an influx of patients quickly and efficiently.



Portfolio highlights:

- > Surge Capacity Management Support
- > Home Monitoring and Telemedicine Solutions
- > Infection Control and Prevention Solutions



Surge Capacity Management Support

Rapidly respond to an increase in patient volume:

- > Quickly adapt non-clinical spaces into advanced care environments with a range of out-of-the box Pulse CO-Oximeters® and vital signs monitors
- > Remotely monitor all patients at a glance at a centralised view station with Patient SafetyNet™*
 - With **Replica[™]**, view and respond to alarms and alerts from a smartphone, regardless of location
- > Use Early Warning Scores (EWS), configured per hospital protocol, to quickly assess patient status
- > Support patients suffering from pulmonary conditions and respiratory distress with TNI softFlow[®] 50, nasal high-flow therapy that administers warmed and humidified respiratory gases through a comfortable nasal cannula









Infection Control and Prevention Solutions

Innovative solutions help care teams minimise transmission risks and increase clinician and patient safety:

- > Immediately convert existing monitoring platforms to single-patient or non-contact solutions to minimse crosscontamination and help manage infection control
- > Tetherless Radius PPG[™] sensors enable the placement of point-of-care monitors outside of a patient's room-ensuring continuous monitoring from a distance
- > Expand visibility of point-of-care monitoring data with wireless supplemental display solutions such as Kite® that can be quickly deployed without any additional IT infrastructure

Home Monitoring and **Telemedicine Solutions**

Masimo supplies a range of advanced remote monitoring solutions that help ensure you can monitor with confidence from a distance, including:

- > Secure cloud-based patient management with Masimo SafetyNet[™], which combines tetherless pulse oximetry with a remote data capture and surveillance platform
- > Compact, hospital-grade portable monitors with supplemental remote monitoring
- > Automated remote care that facilitates the collection of physiological data and patient responses, while providing notification and guidance

*The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium







Convert to single-patient-use sensors, available in a variety of tetherless and tethered styles.

Manage Blood Supplies with SpHb®

In response to blood shortages due to COVID-19, Masimo is offering licenses for rainbow® noninvasive blood constituent monitoring, including total haemoglobin, SpHb®, at no additional charge during the coronavirus pandemic:

- > SpHb provides real-time visibility to changes, or lack of changes, in hemoglobin between invasive blood samplesand has been shown to help clinicians improve patient blood management
- > Available where rainbow[®]-ready devices are already in use

Noninvasively Monitor Methaemoglobin Levels in the Blood

> SpMet[®] helps clinicians monitor methaemoglobin levels in the blood and may be an important monitoring tool during inhaled nitric oxide (iNO) therapy, currently being investigated as a potential treatment for lung complications associated with COVID-19



Support for Screening and Clinical Management Protocols

Advanced Masimo measurements support the implementation of CDC and WHO protocols for fast screening, comprehensive triage, and quality continuous monitoring.^{1,2}



Masimo offers multiple respiration rate monitoring technologies, alongside a variety of spot-check and continuous monitors designed for use with single-patient-use products:



Respiration rate from the Pleth (RRp)





NomoLine[®] Capnography (RRc™)



Contact Masimo to discuss how we can help you stay safe.

SpHb and SpMet are not intended to replace laboratory blood testing. Clinical decisions regarding red blood cell transfusions should be based on the clinician's judgment considering, among other factors, patient condition and laboratory diagnostic tests using blood samples.

¹World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected. Interim Guidance 28 January 2020. ²Centers for Disease Control and Prevention. Human Infection with 2019 Novel Coronavirus Person Under Investigation (PUI) and Case Report Form. Approved: OMB: 0920-1011.

TNI softFlow 50 is not licensed for sale in Canada.

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, and precautions.

Masimo U.S. tel 1-877-4-Masimo info-america@masimo.com Masimo International tel +41-32-720-1111 info-international@masimo.com

